| CEOs routinely set goals and make pledges as part of their pitches, and most work hard to keep them—but still, some end up going back on their word. In M&A, litigation and more, the past few years have seen a slew of broken promises, or some that have yet to be met, at least. And while “forward-looking statements” warn against uncertain futures—and changing circumstances often mean changing strategies—it’s still worth keeping track of what’s been guaranteed. | |
|
Featured Story | | | Tuesday, October 29, 2019 When Mylan and Pfizer's Upjohn business trumpeted their merger in July, it marked a major coup for the generics maker's shareholders after a rough couple of years. Turns out the deal wasn't just profitable for Mylan's investors—it was also a big score for Mylan's C-suite. |
|
|---|
|
Top Stories Of The Week Monday, October 28, 2019 CEOs for Bayer, AbbVie, Allergan and other companies others appear in our report featuring the top broken promises in biopharma. Wednesday, October 30, 2019 As Amgen rides the wave of hype and hope for its early-stage KRAS effort as well as other cancer assets in its pipeline, this is pushing out its work on neuroscience. Tuesday, October 29, 2019 Last July, Pfizer decided to reorganize and lumped off-patent drugs into an autonomous unit. A month later, Mylan launched a strategic review to appease restive shareholders. Once the two companies realized they had common ground—and Pfizer CEO Albert Bourla made a well-timed phone call—they struck a deal in less than 90 days. Monday, October 28, 2019 David Hung, M.D., has had a strange few years: Going from the man who led Medivation into being snapped up by Pfizer in a major $14 billion M&A deal, he then went over to Axovant, where it went very wrong. Friday, October 25, 2019 A clutch of Gilead drugs including filgotinib have failed to move the needle in midphase clinical trials of cutaneous lupus and Sjogren's syndrome patients. Neither trial hit the primary endpoint, although Gilead did see “evidence of activity” in patients taking filgotinib. Friday, October 25, 2019 Amgen cut the list price of its PCSK9 cholesterol drug Repatha from $14,520 to $5,850 last year but maintained the pricier option for insurers who preferred to take it, along with what were likely steep discounts. Now, Amgen is doing away with the high-priced version of the product. But will that be enough to boost demand? Wednesday, October 30, 2019 Novartis' bid to expand Zolgensma's market has suffered a setback. After a safety red flag emerged in an animal study, the FDA halted enrollment in a trial testing the gene therapy's new spinal-injection formula. At best, it's a delay for the drugmaker's plan to treat older, later-onset patients. Monday, October 28, 2019 Gilead Sciences has tapped FierceMedTech Fierce 15 winner Glympse Bio to help develop a non-invasive diagnostic test for nonalcoholic steatohepatitis, also known as the fatty liver disease NASH. Tuesday, October 29, 2019 Researchers at the Francis Crick Institute have identified a key mechanism that controls how cancer cells degrade their surrounding scaffolds to migrate to other locations. Targeting the process could with drugs could stop cancer from spreading, they argue. Wednesday, October 30, 2019 Merck & Co. won’t be able to fully meet global demand for HPV vaccine Gardasil until after 2023 when it completes production of a couple of manufacturing plants. So for now, the drugmaker is again turning to the CDC to borrow doses. Resources Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. | 
